Kornimate/medical-research-clean huggingface dataset:
bilio-pancreatic complications of congenital duodenal obstructions

Conditions: Duodenal Obstruction

Summary: congenital duodenal obstructions, often grouped under the term duodenal atresias, encompass a range of malformations of the duodenum that cause partial or complete obstruction. in the long term, the main complications described fall within the spectrum of digestive occlusions (anastomotic stenosis, obstruction due to adhesions, and duodenal dysmotility) and may require surgical revisions. biliary and pancreatic complications, which are embryologically logical, are reported in the form of rare clinical cases. the aim of the research is to identify biliopancreatic complications following duodenal atresia surgery in order to characterize them, estimate their national frequency, and determine any potential iatrogenic risk factors.


Eligibility criteria:
inclusion criteria: * patients who underwent surgery for duodenal atresia in a pediatric surgery department participating in the study over the past 20 years, * legal representatives did not object to data collection exclusion criteria: * patients ≥ 16 years at the time of surgery. * objection from the legal representatives of the child or the adult patient to the collection and use of health data
influence of postoperative cognitive function in patients with sevoflurane postconditioning on carotid intima stripped

Conditions: Postoperative Cognitive Dysfunction; Sevoflurane; Carotid Artery Intima Stripped

Summary: brief summary: in order to get a better clinical plan for brain protection during perioperative anesthesia for high-risk patients - carotid intima stripped. we observing the hemodynamic changes of sevoflurane post-treatment in carotid intima stripped, the comparison of postoperative cognitive function and postoperative radiographic changes.


Eligibility criteria:
inclusion criteria: * american society of anesthesiologists（asa）：ii-iii * aged between 40 and 80 years * patients scheduled for surgery of carotid stenosis under general anaesthesia exclusion criteria: * has a history of mental illness can't cooperate, * serious heart block or cardiac decompensation or severe sinus slow (hr \< 50 times/min), * the abnormal nerve monitoring in operation, mmes preoperative score \< 20 points, * any rescue unexpected occurred during the operation
spectrum of bacterial infections in rheumatology

Conditions: Articular Disease

Summary: retrospective study of patients with a proved non-tuberculous osteoarticular infection (oai) diagnosed in a rheumatology department during the years 2010-2020. the objectives are : * to describe sites, type of micro-organism, clinical data, origin of infection, therapeutic modalities et outcome * to compare oai of urinary origin with those with another origin

this retrospective study will be conducted on medical files. patients will be mainly selected on : * a proved osteoarticular infection (oai) diagnosed in the department of rheumatology of the rené dubos hospital from 1° january 2010 to 31 december 2020. * adult patients 18 year's old or older * infection proved by positive culture in the osteoarticular site and/or blood (with typical clinical and imaging features) the followed oai are not included : * infection on prosthetic joint, materiel ; post-operative oai ; osteomyelitis * brucellosis ; lyme disease patients are selected from the codification of the hospitalization ; medical files are reviewed by the investigators. oai of urinary origin is defined either by the same micro-organism in urine and osteo-articular sample (or blood) or a bacteria in the osteo-articular sample in conjunction with : urologic pathology, recurrent urinary tract infection, urologic surgery, antibiotic therapy. * characteristics of three populations will be compared : * - oai of urinary origin * - oai of another origin (skin, etc) * - oai without known origin characteristics include : gender, age, risk factors, site of osteo-articular infection, type of micro-organism, type of positive sample(s), blood cultures, urinary cultures, duration of symptoms, site of primary infection and/or type of contamination, biological results, echocardiography, imaging results, type of treatment (medical, surgical), outcome, duration of hospitalization, intensive unit care stay, death at hospital.

Eligibility criteria:
inclusion criteria: * subject aged 18 years and over at the time of diagnosis * osteoarticular infection (septic arthritis, spondylodiscitis), by a bacterium or a fungus, proven by a bacteriological sample in situ or in the blood by positive blood culture (with an unequivocal clinical, biological and imaging feature), * diagnosed between 01/01/2010 and 12/31/2020 (11 years) * hospitalization in the rheumatology department of ch rené dubos, pontoise exclusion criteria: * bacterial infection due to the following germs: mycobacteria, brucella, borrelia * early infection on joint prosthesis * peripheral osteomyelitis * osteoarticular infection without bacteriological proof

Keywords: osteoarticular infection bacteria urinary tract infections
measurement of the energy metabolism of peritoneal dialysis patients

Conditions: Renal Failure

Summary: the daily energy expenditure of patients treated with peritoneal dialysis could be increased compared to the general population and promote the development of a state of undernutrition. conversely, the absorption of glucose by transperitoneal route could contribute to the occurrence of a metabolic syndrome. the main objective is to compare de and its variations according to the conditions (rest, sleep, meals, physical activity) in patients treated with automated dp compared to controls, in a calorimetric chamber.

the daily energy expenditure of patients treated with peritoneal dialysis could be increased compared to the general population and promote the development of a state of undernutrition. conversely, the absorption of glucose by transperitoneal route could contribute to the occurrence of a metabolic syndrome. the main objective is to compare de and its variations according to the conditions (rest, sleep, meals, physical activity) in patients treated with automated dp compared to controls, in a calorimetric chamber.

Eligibility criteria:
inclusion criteria: * patients group dpa * male patients * aged 18 to 70 years * with end-stage renal disease * treated by automatic peritoneal * social security cover * without acute events in the 3 months prior to inclusion * pcr \< 30 mg/l * written informed consent * baecke activity score from 5 to 10 healthy volunteers * male patients * aged 18 to 70 years * patients matched by lean body mass (± 2 kgs) and age (± 5 years) * having a glomerular filtration rate estimated with the formula ckd-epi creatinine \> 60 ml / min / 1.73 m 2 * pcr \< 3 mg/l * social security cover * written informed consent * baecke activity score from 5 to 10 exclusion criteria: * • - female * type 1 or 2 diabetes requiring a antidiabetic treatment * decompensated heart failure * smoking more than 5 cigarettes a day * alcoholic patients, drinking more than 3 glass of alcohol a day * patient corticotherapy in progress * patient with evolutive acute pathology * person who has participated in another study within the last 30 days or is in period of exclusion on the national file of healthy volunteers

Keywords: energy expenditure peritoneal dialysis
high inspiratory oxygen fraction on endothelial function in healthy volunteers

Conditions: Endothelial Dysfunction

Summary: the frequency of preoperative cardiac ischemia and the 30-days postoperative mortality is much higher than previously assumed, with approximately 10 % of patients undergoing non-cardiac surgery suffering from postoperative myocardial injury. a recent danish study furthermore showed that patients treated with a high inspiratory oxygen fraction during surgery had a higher 1 year mortality compared with patients treated with a low inspiratory fraction. this was especially significant among patients undergoing cancer surgery. a possible explanation, is that a high oxygen fraction results in oxidative stress and endothelial dysfunction. with this randomized cross-over study we wish to investigate the effect of a high inspiratory oxygen fraction on the endothelial function among healthy male volunteers. the primary outcome is the endothelial function assessed by the endopat system. secondary outcomes are changes in oxidative biomarkers. heart rate variability (hrv) recordings will serve as a measure for the effect of oxygen on the autonomic nervous system.


Eligibility criteria:
inclusion criteria: * healthy male volunteers between 18 and 30 years who has given an oral and written informed consent exclusion criteria: * smoking, or ex-smoker any kind of medication on a daily basis history of atopic dermatitis known familiar hypercholesterolemia history of arteriosclerotic disease in the first and second-degree relatives known or unknown arrhythmias, as measured by the baseline hrv-recording

Keywords: oxidative stress nitrogen oxide reactive oxygen species
a trial of hrs-7535 tablets in subjects with overweight or obesity

Conditions: Overweight; Obesity

Summary: the study is being conducted to evaluate the efficacy and safety of hrs-7535 in subjects with overweight or obesity.


Eligibility criteria:
inclusion criteria: 1. on the day of signing the informed consent form, the age should be between 18 and 75 years old. 2. at the screening period, the body mass index (bmi) should meet the criteria of ≥ 28.0 kg/m², or ≥ 24.0 kg/m² with at least one weight-related comorbidity, such as hyperglycemia, hypertension, dyslipidemia, obstructive sleep apnea, or non-alcoholic fatty liver disease. 3. the participant should have controlled their diet and exercise for 3 months or more prior to screening and randomization, and the weight change in the past 3 months should not exceed 5%. 4. before the trial, the participants must voluntarily sign the informed consent form, fully understand the trial content, procedures and potential adverse reactions, and have the ability and willingness to comply with the protocol requirements to complete this study. exclusion criteria: 1. at the screening period, relevant laboratory test results are abnormal. 2. electrocardiogram (ecg) results at the screening period show clinically significant abnormalities. 3. uncontrolled severe hypertension at the screening period. 4. presence of endocrine diseases that may significantly affect the body weight. 5. history of acute or chronic pancreatitis. 6. history of significant gastrointestinal diseases. 7. severe infections, significant trauma, or major surgery within 30 days prior to screening, as judged by the investigator. 8. use of medications or treatments that may cause significant weight gain or loss within 90 days prior to screening. 9. known or suspected abuse of alcohol or narcotics. 10. any condition deemed by the investigator to be unsuitable for participation in this clinical trial.
optical genome mapping in characterization of multiple myeloma

Conditions: Multiple Myeloma

Summary: the current cytogenetic characterization of multiple myeloma (including chromosome and gene abnormalities identification in abnormal plasma cells) encounters some limitations. indeed current techniques only enable to analyze a limited numbers of predefined abnormalities. new tools that will allow for characterization of abnormalities involved in multiple myeloma development are thus required. the interest of optical genome mapping has already been demonstrated in other hematological diseases. the present study aims at validating optical genome mapping in genetic abnormalities identification for patients with multiple myeloma (mm).

for this study, supplementary samples will be collected during bone marrow biopsy performed at mm diagnosis. these will be used for cd138+ plasma cell isolation and sent to gentyane (genotypage and sequencing in auvergne) platform in clermont-ferrand for optical genome mapping.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * non previously treated multiple myeloma (criteria from the international myeloma working group) * presence of crab criteria (calcium renal anemia bone : calcemia \> 2.75 mmol/l or \> 0.25 mmol/l higher than the upper limit of normal ; serum creatinine \> 173 μmol/l or creatinine clearance \< 40ml per minute attributed to myeloma ; anemia with hemoglobin value \< 10g/dl or more than 2g/dl below the lower limit of normal, bone lesions with osteolytic lesions or osteoporotic vertebral collapses attributed to myeloma) exclusion criteria: * opposition of the patient * failure of myelogram * previous treatment of multiple myeloma (except with corticosteroids) * failure of fish * minor or patients placed under guardianship or supervision * patients deprived of liberty * patients placed under judicial protection * patients that are not able to express their consent * pregnant and breastfeeding women
robot-assisted therapy in stroke patients

Conditions: Cerebrovascular Accidents; Stroke

Summary: this project consists of two parts: robotic rehabilitation trials, and study of outcome predictors and clinimetric attributes. in the first part of study, the investigators aim to (1) investigate the treatment effects of robot-assisted therapy (rat) in patients with stroke on various outcomes, (2) test the dose-response relations by using two different intensities (higher versus lower intensity rat), and (3) investigate the effects of the training intensity on a biomarker of oxidative stress. treatment outcomes will encompass the spectrum of functioning including motor ability, motor control strategies, basic/extended daily functions, mobility, community reintegration, quality of life, and biomarker (8-ohdg). in the second part of study, the purposes are to define the appropriate populations for rat and to examine the clinimetric properties of clinical measures relevant for use in robotic rehabilitation research. the investigators will identify the clinical predictors that will potentially influence the functional outcomes after interventions. finally, the investigators will examine and compare the clinimetric properties (e.g., validity and responsiveness) of the clinical measures of rehabilitation outcome to inform selection of test instruments that may detect clinically meaningful change after rehabilitation therapy.


Eligibility criteria:
inclusion criteria: 1. 3 to 24 months onset from a first-ever unilateral stroke 2. an initial ul subsection of the fugl-meyer assessment score of 18 to 56 indicating moderate to severe and moderate ul movement impairment 3. no excessive spasticity in any of the joints of the affected ul (shoulder, elbow, wrist, fingers) 4. be able to follow study instructions and perform study tasks 5. without upper limb fracture within 3 months 6. lack of participation in any experimental rehabilitation or drug studies during the study period 7. willing to provide written informed consent exclusion criteria: 1. subjects exhibiting physician-determined major medical problems or poor physical conditions that would interfere with participation 2. subjects with excessive pain in any joint that might limit participation
a study the population pharmacokinetics of children of infectious disease in central nervous system

Conditions: Central Nervous System Infection

Summary: the investigators aim to study the population pharmacokinetics of children receiving the anti-infective drugs for treatment of infectious disease in central nervous system.

the investigators aim to study the population pharmacokinetics of children receiving the anti-infective drugs for treatment of infectious disease in central nervous system.in this study, the investigators will detect drug concentration in plasma by using residual blood samples of blood gas analysis and other clinical tests and employ computers for constructing population pharmacokinetic models.

Eligibility criteria:
inclusion criteria: * children (29 days-18 years old) with anti-infective therapy against infectious disease in central nervous system. * clinical symptoms: acute onset, fever (axillary temperature 38 ℃ or higher), headache, altered level of consciousness, vomiting, irritability, sleepiness, low muscle tone, seizures, before the fontanelle full or uplift, positive meningeal stimulation; * aboratory examination: csf appearance change, csf routine wbc \>100 per ml, csf routine wbc 10-100 per ml, glucose \ 100mg/dl), positive detection of etiology (bacterial culture, antigen detection, gram staining). exclusion criteria: * autoimmune encephalitis; * central nervous system infection complicated with tumor; * allergic to carbapenems or glycopeptide antibiotics; * other cases not suitable for enrollment (small sample size, incomplete clinical data, etc.).
armonia: an observational study of biologic drugs in monotherapy or combination with dmards in italian clinical practice and the efficacy and safety of roactemra/actemra (tocilizumab) monotherapy in patients with rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: this is a multicenter observational study in patients with rheumatoid arthritis in routine clinical practice in italy. in the retrospective part 1 of the study, clinical and demographic factors associated with the use of a biologic drug in monotherapy as compared to therapy in combination with disease-modifying anti-rheumatic drugs (dmards) will be evaluated. in the retrospective/prospective part 2 of the study, efficacy and safety of the use of roactemra/actemra (tocilizumab) in monotherapy will be evaluated. patients will be followed for up to18 months.


Eligibility criteria:
inclusion criteria: part 1: * adult patients, \>/= 18 years of age * diagnosis of rheumatoid arthritis according to american college of rheumatology (acr)/ european league against rheumatism (eular) criteria * patients who received at least one cycle of biologic therapy, either in monotherapy or in combination, in the 12 months preceding the opening of the first site part 2: * patients on monotherapy with roactemra/actemra already enrolled in part 1 of the study exclusion criteria: * patients simultaneously participating in other studies with roactemra/actemra at the time of signing informed consent
pulmonary hypertension in left heart disease

Conditions: Pulmonary Hypertension; Pulmonary Vascular Disease; Left Heart Disease

Summary: the goal is to compare patients with and without varying severity of pulmonary vascular disease based upon hemodynamic signatures, echocardiographic measures, and lung ultrasound, in tandem with expired gas metabolic testing and blood sampling.


Eligibility criteria:
inclusion criteria: * patients referred to the cardiac catheterization laboratory for invasive right heart catheterization for any reason. * left heart disease, defined as one (or more) of the following: * symptomatic hfpef, defined by signs and symptoms of hf (dyspnea, fatigue), normal left ventricular (lv) ef (≥50% within 12 months of enrollment), and objective evidence of hf fulfilling at least one of the following criteria: prior hospitalization for decompensated hf treated with intravenous diuretics; invasively verified hfpef defined by pulmonary capillary wedge pressure (pcwp) of ≥15 mmhg at rest and/or ≥25 mmhg during exercise; clinical diagnosis of hfpef that does not meet criteria i. or ii. but verified with ntprobnp\>300 pg/ml in sinus rhythm or \>900 pg/ml in af; h2fpef score ≥6 or hfa-peff score≥5 according to current guidelines. * symptomatic hfref, defined by defined by signs and symptoms of hf (dyspnea, fatigue) and reduced ef (\<50%). * symptomatic valvular heart disease (vhd), defined by signs and symptoms of hf (dyspnea, fatigue) in tandem with clinically significant aortic or mitral valve disease (regurgitation and/or stenosis). exclusion criteria: * patient inability or unwillingness to undergo noninvasive echocardiography, or if echocardiography would, in the opinion of the investigator, somehow compromise the quality of data acquisition for the clinical case. * wsph group 1 pulmonary hypertension or ph (pulmonary arterial hypertension; including congenital heart disease) * group 3 ph (hypoxia/lung disease-related ph) * group 4 ph (thromboembolic ph) * group 5 ph (miscellaneous) * clinically significant parenchymal lung disease, hypoxemia, or lung infection * amyloid/infiltrative cardiomyopathy * acute myocarditis * acute coronary syndrome or revascularization within 90 days * use of ph-specific drugs * constrictive pericarditis * high output heart failure * hf hospitalization within the preceding 30 days * severe or greater aortic (ava \ 40 mmhg) or severe mitral (mva \< 1.0 cm) stenosis * inability or unwillingness to exercise * inadequate echocardiographic imaging windows * inability or unwillingness to cooperate with breath holding
safety, tolerability, pharmacokinetics and efficacy of lmb763 in patients with nash

Conditions: Non-alcoholic Steatohepatitis NASH

Summary: the purpose of the present study is to assess the effects of lmb763 with respect to safety, tolerability, and on markers of liver inflammation in patients with nash


Eligibility criteria:
inclusion criteria: * male/female patients, 18 years or older * written informed consent * presence of nash by histologic evidence (liver biopsy) and elevated alanine aminotransferase (alt), or phenotypic diagnosis of nash based on elevated alt, bmi and diagnosis of type 2 diabetes mellitus exclusion criteria: * current use of obeticholic acid (oca) * new initiation glp-1 agonists such as liraglutide, exenatide , lixisenatide, albiglutide or dulaglutide within 3 months of screening * pregnant or nursing (lactating) women * women of child-bearing potential, unless they are using highly effective methods of contraception during dosing and for 5 days after stopping study medication * current or history of significant alcohol consumption for a period of more than 3 consecutive months within 1 year prior to screening * clinical evidence of hepatic decompensation or severe liver impairment * previous diagnosis of other forms of chronic liver disease * uncontrolled diabetes mellitus * history or current diagnosis of ecg abnormalities * patients with contraindications to mri imaging

Keywords: non-alcoholic steatohepatitis nash fatty liver disease
multicenter validation of a predictor model of achd patients and cardiac surgery

Conditions: Adult Congenital Heart Disease; Cardiac Surgery

Summary: this multicentre study is to validate prediction modeling for the achd population undergoing cardiac surgery. the validation of this prediction model will support and generalize its use as a risk stratification tool in the achd population.

the prediction model resulted from a preceding study, which uniquely based on comorbidities, was developed using 783 adults (\>16 years) who underwent surgery for congenital heart disease at toronto general hospital (tgh) during 2004-2015. it identifies five pre-operative variables, namely presence of cognitive impairment, hepatic function, \>3 chest incisions, anatomy diagnosis, and body mass index \ 28, as significant predictors of composite adverse outcomes such as in-hospital mortality, prolonged ventilation (exceeding 7 days) and acute kidney injury. this newly prediction model developed in a single-center has only been internally validated. it requires further external validation to demonstrate its utility in achd populations who require cardiac surgery in other cardiac institutions both nationally and internationally.

Eligibility criteria:
inclusion criteria: * all achd patients \>16 years of age undergoing cardiac surgery requiring an open sternotomy or thoracotomy and cardiopulmonary bypass (cpb) or cpb standby at tgh and the collaborating institutions from april 2019. exclusion criteria: * chd patients \<16 years of age * achd patients undergoing chest wall debridement and chest re-explorations for bleeding * non-cardiac surgery procedures and cardiology laboratory interventions

Keywords: prediction model